## **Corporate Action Notice**

November 22, 2017

## **Reverse Stock Split**

Lynas Corporation Limited DR CUSIP: 551073208 DR ISIN: US5510732085 DR Ticker Symbol: LYSDY

Ratio (DRs: Underlying Shares): 1:1

Please be advised that Lynas Corporation Limited ("Lynas") has announced a share consolidation of one (1) new share for every ten (10) existing shares. The share consolidation is subject to approval at Lynas's Annual General Meeting to be held on November 28, 2017.

As a result, if the share consolidation is approved at the Annual General Meeting, BNY Mellon will effect a reverse stock split on the Lynas Depositary Receipt ("DR") program. Effective December 4, 2017, DR holders of Lynas are required on a mandatory basis to surrender their DR(s) to BNY Mellon for cancellation and exchange to receive one (1) "New" Depositary Share ("DS") (CUSIP TBD) for every ten (10) "Old" DSs (CUSIP 551073208). Holders of DSs in the Direct Registration System or in brokerage accounts will have their DRs automatically exchanged and need not take any action. No fraction of a DS will be issued. BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds to DR holders.

## Below are the pertinent details:

Effective date: December 4, 2017

Exchange Rate: 1 new DS for every 10 old DSs

 Old CUSIP:
 551073208

 New CUSIP:
 TBD

 Cancellation Fee:
 \$0.004860

The existing ratio of one (1) Depositary Share representing one (1) ordinary share will remain the same.

BNY Mellon's books will be closed for all issuance and cancellation transactions on CUSIP 551073208 as of the close of business November 30, 2017. BNY Mellon expects to reopen the books on CUSIP TBD on December 8, 2017.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

## NEW YORK LONDON

Ravi Davis Jacek Jankowski
Richard J Maehr Vice President
+ 1 212 815 2267 + 44 207 163 7427

adrdesk@bnymellon.com jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/drissuers/asset\_upload\_file49220\_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of

